Patient satisfaction with calcipotriol/betamethasone dipropionate cutaneous foam for the treatment of plaque psoriasis: The LION real-life multicenter prospective observational cohort study

Gianfranco Damiani, Ketty Peris, Maria Concetta Fargnoli, Anna Campanati, Laura Atzori, Concetta Potenza, Giovanni Damiani, Luca Bianchi, Monica Corazza, Rossana Tiberio, Francesca Prignano, Giuseppe Argenziano, Luca Stingeni, Annamaria Mazzotta, Ornella De Pità, Carlo Mazzatenta, Claudio Feliciani, Massimo Donini, Annamaria Offidani

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Topical treatment is the mainstay for mild or moderate psoriasis, but patients are generally little satisfied. Calcipotriol/betamethasone dipropionate (Cal/BD) cutaneous foam has shown to improve signs and symptoms in plaque psoriasis patients. This study assessed patient's satisfaction with Cal/BD foam in a real-life Italian dermatological clinical practice. A multicenter, 4-week observational prospective cohort study enrolled, in 17 Italian dermatology clinics, adult patients with plaque psoriasis on the body and/or scalp. Treatment satisfaction was assessed by 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9), preference over previous treatments by Patient Preference Questionnaire (PPQ), and change in disease state by Psoriasis Area Severity Index (PASI). Overall 256 patients were eligible, with a mean (SD) age of 55.6 (15.4) years, 59.4% were males. Psoriasis severity was mild in 52.0% of patients, moderate in 43.3%, and severe in 4.7%. Scalp involvement was present in 36.7% of patients. Previous antipsoriatic treatments had been received by 80.5% of patients. TSQM-9 median (25th-75th percentile) scores were 83.3 (66.7-88.9) for effectiveness, 77.8 (66.7-88.9) for convenience, and 78.6 (64.3-92.9) for global satisfaction. Mean (SD) PASI value decreased from 7.3 (4.8) to 2.1 (2.7) after 4 weeks. More than 90% of patients previously treated for psoriasis evaluated the Cal/BD foam more effective, easier to use and better tolerated compared to previous topical treatments at PPQ. This observational study provides real-life evidence of a high level of satisfaction with effectiveness and convenience of the Cal/BD foam in a cohort of plaque psoriasis patients, with an objective improvement in PASI.
Lingua originaleEnglish
pagine (da-a)e15077-N/A
RivistaDermatologic Therapy
Volume34
DOI
Stato di pubblicazionePubblicato - 2021

Keywords

  • psoriasis
  • therapy-topical
  • Adult
  • Betamethasone
  • Calcitriol
  • Drug Combinations
  • Psoriasis
  • Male
  • Middle Aged
  • Patient Satisfaction
  • Prospective Studies
  • Treatment Outcome
  • Dermatologic Agents
  • Humans

Fingerprint

Entra nei temi di ricerca di 'Patient satisfaction with calcipotriol/betamethasone dipropionate cutaneous foam for the treatment of plaque psoriasis: The LION real-life multicenter prospective observational cohort study'. Insieme formano una fingerprint unica.

Cita questo